Nitin Gosar

Hi, team. Wanted to understand 2 aspects. Now keeping in mind that the Branded Generics forms a very dominant share of our revenue, and the outlook in Branded Generics is somewhere around 10%, 12%, 13% kind of a growth. And the U.S. becomes the only key moving part to driv e the additional growth.

That's a fair point. And in the opening remarks, there was mention ing of high cash flow generation, but vis-a-vis that if I were to see the 9-month interest outgo is around Rs. 15 crores versus last year 9 months around Rs. 6 crores. Why should be that be, sir?

Okay. And should now this become the norm for us?

Thank you for this call just taking from the previous participant question wanted to understand again on the IP part at what stage we are in terms of IP utilization or are the IP capabilities that we have developed allowing us to bid for complex projects or the IP capabilities that we have developed are allowing us to bid at a lower price, how should we distinguish between these two?

Got it and that is what you indicated the speed is the essence in terms of servicing the market . Second question is with regard to a cost metric s keeping in mind now we are in position to scale up our business should we expect the cost metrics at least the fix ed cost part to grow or to stay where it is how should we look at that?

Got it and Sir last bit I know you a re not for the competitive reason in position to dwell out on the gross margins but would it be good enough to understand the current quarter where we are and the gross margins we could be having are the appropriate margin the business would command or there is some kind of one-off or something?